Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Elan report positive Tysabri results

Biogen Idec and Elan report positive Tysabri results

20th August 2007

Biogen Idec and Tysabri have announced the publication of positive phase III clinical trial results showing that multiple sclerosis patients administered with Tysabri (natalizumab) exhibited an improvement in health-related quality of life.

The study – presented in the current issue of Annals of Neurology – measured health-related quality of life using the Short Form-36 and Visual Analogue Scale measurements at weeks 24, 52 and 104 of treatment, in addition to measuring baseline figures.

In the trial, patients showed a continued improvement from baseline figures, not merely a slowdown in deterioration.

The Affirm and Sentinel studies involved 2,113 patients with relapsing forms of multiple sclerosis.

Richard Rudick, director of the Mellen Centre for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, said: “These data showed that patients treated with Tysabri were more likely to experience statistically important improvement in the quality-of-life measures used to assess meaningful disease improvement or progression.”

He added that such results have not been previously observed in clinical trials involving patients with multiple sclerosis.

Last month, Biogen Idec and Elan announced the first anniversary of the launch of Tysabri in the European Union, reporting that over 4,300 patients are using the compound commercially in the region.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.